Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases and cancer, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $108M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 24.07.2020 | - | $60M | Omega Fund... | - |
| 13.06.2016 | Series A | $48M | - | vcnewsdail... |
Mentions in press and media 11
| Date | Title | Description | Source |
| 24.10.2022 | Alpine stops enrollment in cancer drug study after second pa... | A patient has died in a clinical trial testing an experimental Alpine Immune Sciences cancer immunot... | medcitynew... |
| 20.09.2022 | Alpine Immune Sciences Announces Pricing of $100 Million Pub... | - | orbimed.co... |
| 15.09.2021 | Three Democrat reps oppose Medicare drug pricing plan; ... | A trio of key Democrats said yesterday they will oppose their party’s plan to lower drug pric... | endpts.com... |
| 24.05.2019 | Life sciences fund raises €118M for its next round of bets... | → A small but growing transatlantic biotech investor is getting a fresh shot in the arm for its ... | endpts.com... |
| 01.02.2019 | Seattle Venture Capital Watch: Alpine Immune, Wyze, Aduro, G... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Welcome to February! Whether your ... | xconomy.co... |
| 18.04.2017 | Ex-Dendreon chief Mitch Gold steers his way back to the pub... | Mitch Gold is coming back to the helm of a public biotech company. The former Dendreon CEO — ... | endpts.com... |
| 13.06.2016 | Alpine Immune Sciences Grabs $48M Series A | SEATTLE, WA, Alpine Immune Sciences announced the closing of its $48 million Series A financing ro... | vcnewsdail... |
| 13.06.2016 | OrbiMed Leads $48M Series A for Alpine Immune Sciences | SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology compan... | citybizlis... |
| 13.06.2016 | Alpine Immune Sciences Closes $48M Series A Financing Round | Alpine Immune Sciences, Inc., a Seattle, WA-based biotechnology company developing an immune system ... | finsmes.co... |
| 05.02.2015 | Former Dendreon CEO launches stealth next-gen immunotherapy ... | Dendreon is known for launching Provenge, a prostate cancer drug that was the first-ever immunothera... | medcitynew... |
Show more